|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
Basic Trial Information
Summary The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in patients with multiple myeloma who have received no prior treatment. This study will evaluate whether the addition of Revlimid to VELCADE and Dexamethasone will increase the CR/ very good partial response (VGPR) rate. Eligibility Criteria Inclusion Criteria: 1. Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. 2. Male or female subject 18 years of age or older 3. A Karnofsky Performance Status score of ≥50% (Eastern Cooperative Oncology Group Performance Status score ≤2) 4. Subjects must have symptomatic myeloma or asymptomatic myeloma with myeloma-related organ damage 5. Multiple myeloma diagnosed according to the following standard criteria: Major criteria
Minor criteria
Any of the following sets of criteria will confirm the diagnosis of multiple myeloma
6. Subjects must have measurable disease requiring systemic therapy. Measurable disease is defined by at least 1 of the following 3 measurements:
7. Subjects must not have been treated previously with any systemic therapy for multiple myeloma. Prior treatment with corticosteroids or radiation therapy does not disqualify the subject (the maximum dose of corticosteroids should not exceed the equivalent of 160 mg of dexamethasone1 in a 2-week period). 8. Two weeks must have elapsed since the date of the last radiotherapy treatment. Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 2 weeks have elapsed since the last date of therapy. 9. Women of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 to 14 days prior to therapy and repeated within 24 hours before starting study drug. They must commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of birth control (1 highly effective method and 1 additional effective method) used at the same time, beginning at least 4 weeks before initiation of Revlimid treatment. Women must also agree to ongoing pregnancy testing. (See section 7.4.8.1 for further details regarding the frequency of pregnancy testing and acceptable methods of birth control.) 10. Men must agree to not father a child and agree to use a latex condom during therapy and for 4 weeks after the last dose of study drug, even if they have had a successful vasectomy, if their partner is of childbearing potential. 11. All subjects must agree to comply with the requirements of the RevAssistSM program. Exclusion Criteria: 1. History of allergy to any of the study medications, their analogues, or excipients in the various formulations 2. ≥Grade 2 peripheral neuropathy on clinical examination 3. Serum creatinine ≥2.5 mg/dL 4. Absolute neutrophil count (ANC)<1000 per µL 5. Platelet count <70,000 per µL 6. Aspartate transaminase (AST [SGOT]) and alanine transaminase (ALT [SGPT]) >2 × the upper limit of normal (ULN) 7. Total bilirubin >3 × ULN 8. Myocardial infarction within 6 months prior to enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or clinically significant conduction system abnormalities. 9. Female subject who is pregnant or breast-feeding 10. Clinically relevant active infection or serious comorbid medical conditions 11. Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the subject at unacceptable risk if he/she were to participate in the study. This includes but is not limited to serious medical or psychiatric illness likely to interfere with participation in this clinical study. 12. Active prior malignancy diagnosed or treated within the last 3 years Trial Lead Organizations/Sponsors Millennium Pharmaceuticals, Incorporated Johnson & Johnson Pharmaceutical Research & Development, LLC
Trial Sites
Link to the current ClinicalTrials.gov record. Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |